DOI: 10.1055/s-00000007

Aktuelle Urologie


Siefker-Radtke AO, Necchi A, Park SH. et al.
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

Journal of Clinical Oncology 2018;
36: 4503

Download Bibliographical Data

Search in: